Las Condes

124 / 164

254
44. Egan AG, Blind E, Dunder K, De Graeff PA, Hummer T, Bourcier T
et al. Pancreatic Safety of Incretin-Based Drugs - FDA and EMA
Assessment. N Engl J Med. 2014;370:794-797.
45. FDA Guidance for industry diabetes mellitus-evaluating
cardiovascular risk in new antidiabetic therapies to treat type
2 diabetes. Disponible en:
Drugs/GuidanceComplianceRegulator yInformation/
Guidances/ucm071627
46. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber
LV, et al. ELIXA Investigators. Lixisenatide in Patients with
Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med.
2015;373: 2247-2257.
47. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L, et al. Cardiovascular
safety and glycemic control of glucagon-like peptide-1 receptor
agonists for type 2 diabetes mellitus: A pairwise and network
meta-analysis. Diabetes Res Clin Pract. 2012; 98:386-95.
48. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci
E. Effects of glucagon-like peptide-1 receptor agonists on
cardiovascular risk: A meta-analysis of randomized clinical
trials. Diabetes Obes Metab. 2014; 16:38-47.
49. Irwin N, Flatt PR. New perspectives on exploitation of incretin
peptides for the treatment of diabetes and related disorders.
World J Diabetes 2015; 6(15): 1285-1295.
50. Mittermayer F, Caveney E, De Oliveira C, Gourgiotis L, Puri M,Tai
L-J, and Turner JR. Addressing Unmet Medical Needs in Type
2 Diabetes: A Narrative Review of Drugs under Development.
Current Diabetes Reviews 2015; 11: 17-31.
51. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E,
Nauck M. Management of Hyperglycemia in Type 2 Diabetes,
2015: A Patient- Centered Approach Update to a Position
Statement of the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care
2015; 38:140–149.
52. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like
peptide-1 receptor agonist and basal insulin combination
treatment for the management of type 2 diabetes: a systematic
review and meta-analysis. Lancet 2014; 384: 2228–2234.
53. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the
treatment of type 2 diabetes. Preclinical biology and
mechanism of action. Diabetes Care. 2007; 30: 1335-1343.
54. Chen X-W, He Z-X, Zhou Z-W, Yang T, Zhang X, Yang Y-X et al.
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors
indicated for the treatment of type 2 diabetes mellitus. Clinical
and Experimental Pharmacology and Physiology 2015; 42:
999–1024.
55. Zhong J, Gong Q, Goud A, Srinivasamaharaj S
and Sanjay Rajagopalan. Recent Advances in
Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the
Bench and Clinical Trials. Journal of Diabetes Research 2015.
doi:10.1155/2015/606031.
56. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro
A. et al. The increased dipeptidyl peptidase-4 activity is not
counteracted by optimized glucose control in type 2 diabetes,
but is lower in metformin treated patients. Diabetes Obes
Metab 2012; 14: 518–522.
57. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidylpeptidase
4 is a novel adipokine potentially linking obesity to the
metabolic syndrome. Diabetes 2011; 60: 1917–1925.
58. Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment
of type 2 diabetes: a comparative review. Diabetes, Obesity and
Metabolism 2011; 13: 7–18.
59. Ahren B, Simonsson E, Larsson H , Landin-Olsson M et al.
Inhibition of dipeptidyl peptidase IV improves metabolic
control over a 4-week study period in type 2 diabetes. Diabetes
Care 2002; 25: 869–875.
60. Davidson J A. Incorporating Incretin-Based Therapies Into
Clinical Practice: Differences Between Glucagon-Like Peptide 1
Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors Mayo
Clin Proc. 2010;85:S27-S37.
61. Deacon, C. F. and Lebovitz, H. E. Comparative review of dipeptidyl
peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity
and Metabolism 2016; doi: 10.1111/dom.12610.
62. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab
2011; 15:298-308.
63. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV
inhibition for the treatment of type 2 diabetes: potential
importance of selectivity over dipeptidyl peptidases 8 and 9.
Diabetes 2005;54: 2988-2994.
64. Gooßen K, Gräber S. Longer termsafety of dipeptidyl peptidase-4
inhibitors in patients with type 2 diabetes mellitus: systematic
review and meta-analysis. Diabetes Obes Metab 2012;14:
1061-1072.
65. Capuano A, Sportiello L, Maiorino M, Rossi F, Giugliano D,
Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes
therapy – focus on alogliptin. Drug Des Devel Ther. 2013; 7:
989–1001.
66. Fuchs H, Tillement JP, Urien S, Greischel A, RothW. Concentration
dependent plasma protein binding of the novel dipeptidyl
peptidase 4 inhibitor BI 1356 due to saturable binding to its
target in plasma of mice, rats and humans. J Pharm Pharmacol
2009; 61: 55–62.
67. Scheen AJ.A review of gliptins in 2011. Expert Opin
Pharmacother. 2012;13:81–99.
68. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl
peptidase-4 inhibitors and HbA1c target of \7% in type 2
diabetes: meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2011;13:594–603.
69. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness
of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a
systematic review and mixed treatment comparison. Diabetes
Ther 2014; 5: 1-41.
70. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-
Nilsson I. Efficacy and safety of saxagliptin in combination with
metformin compared with sitagliptin in combination with
metformin in adult patients with type 2 diabetes mellitus.
Diabetes Metab Res Rev. 2010;26:540–549.
71. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso
G. Effects of vildagliptin twice daily vs. sitagliptin once daily on
[REV. MED. CLIN. CONDES - 2016; 27(2) 235-256]